PharmaSGP Holding SE (ETR:PSG)

Market Cap	285.37M
Revenue (ttm)	114.00M
Net Income (ttm)	18.80M
Shares Out	11.99M
EPS (ttm)	1.57
PE Ratio	15.18
Forward PE	10.34
Dividend	1.36 (5.71%)
Ex-Dividend Date	Jun 27, 2024

Volume	1,558
Average Volume	451
Open	23.80
Previous Close	23.80
Day's Range	23.80 - 23.80
52-Week Range	19.00 - 28.00
Beta	-0.07
RSI	43.61
Earnings Date	Apr 29, 2025

About PharmaSGP Holding SE

PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company’s pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for the treatment of hair loss; Dorisol for neuralgia (nerve ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2012
• Employees: 89
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: PSG

Financial Performance

In 2023, PharmaSGP Holding SE's revenue was 101.10 million, an increase of 17.80% compared to the previous year's 85.82 million. Earnings were 16.40 million, an increase of 37.17%.